Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse

NCT00003293 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00003293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 1998
Completion date
May 31, 2001
Enrollment
Not reported
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors